Varenicline is used to help people quit smoking by reducing cravings and withdrawal symptoms, and by blocking the rewarding effects of nicotine if someone relapses.[2] Chantix is currently approved and in use across 33 indications[4].[1]
Chantix is one of 538 small molecule programs targeting Eye Disease. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
744 competitors in Breast Cancer
Chantix
Adenocard
Lexiscan
Voltaren
Zolymbus
Blenoxane
Methylthioninium Chloride
MS Contin
Duragesic-100
MS Contin
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
May 10, 2006
CHANTIX
NDA NDA021928
Oct 15, 2021
TYRVAYA
NDA NDA213978
Sources
Details